Provided by Tiger Trade Technology Pte. Ltd.

Precigen

8.54
+0.33004.02%
Post-market: 8.570.0336+0.39%19:50 EDT
Volume:6.36M
Turnover:53.35M
Market Cap:3.04B
PE:-7.98
High:8.55
Open:8.30
Low:8.18
Close:8.21
52wk High:8.98
52wk Low:2.99
Shares:356.51M
Float Shares:195.00M
Volume Ratio:1.04
T/O Rate:3.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0700
EPS(LYR):-1.3727
ROE:-837.08%
ROA:-18.14%
PB:69.87
PE(LYR):-6.22

Loading ...

Precigen reports Q1 EPS (2c) vs. (18c) last year

TIPRANKS
·
May 14

Stock Track | Precigen Soars 5.78% in After-Hours Trading on Strong Q1 Results and PAPZIMEOS Launch Success

Stock Track
·
May 14

Precigen Q1 revenue beats estimates on PAPZIMEOS launch

Reuters
·
May 14

Earnings Flash (PGEN) Precigen Posts Q1 Per Share Loss $0.02, vs. FactSet Est of $0.02 Loss

MT Newswires Live
·
May 14

Precigen FY26 Q1 net loss narrows to $7.93 million; revenue rises to $23.25 million

Reuters
·
May 14

Precigen Q1 EPS $(0.02), Inline, Sales $23.252M Beat $20.800M Estimate

Benzinga Earnings
·
May 14

Precigen Q1 Net Income USD -7.929 Million

THOMSON REUTERS
·
May 14

Precigen Inc expected to post a loss of 3 cents a share - Earnings Preview

Reuters
·
May 12

Did Strong Early PAPZIMEOS Revenue Guidance Just Shift Precigen's (PGEN) Investment Narrative?

Simply Wall St.
·
May 08

Precigen Inc expected to post a loss of 3 cents a share - Earnings Preview

Reuters
·
May 08

Precigen schedules first-quarter results conference call

Reuters
·
May 08

Top Growth Companies With Insider Stakes In April 2026

Simply Wall St.
·
Apr 28

Is Precigen’s (PGEN) New PAPZIMEOS J-Code Reframing Its Respiratory Growth Narrative?

Simply Wall St.
·
Apr 17

Precigen expects Q1 revenue to exceed $18 million on PAPZIMEOS momentum

Reuters
·
Apr 08

Precigen Expects Q1 Revenue to Surpass $18 Million Due to Strong Uptake of Recurrent Respiratory Papillomatosis Drug

MT Newswires Live
·
Apr 07

GUIDANCE: (PGEN) Precigen Expects Q1 Revenue to Exceed $18M, vs. FactSet Est of $20.8M

MT Newswires Live
·
Apr 07

Precigen sees ‘robust uptake’ in usage of Papzimeos since its launch

TIPRANKS
·
Apr 07